Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05315700 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | PHASE1 | RECRUITING | 350 | — | — | Mar 10, 2022 | Sep 1, 2027 | Aug 5, 2025 | 42 | United States, Australia +8 |
RP2D as determined by interval 3+3 dose escalation design
PK of ORIC-114
PK of ORIC-114
PK of ORIC-114
PK of ORIC-114
| Arm | Type | Description |
|---|---|---|
| Dose Escalation and Dose Optimization | EXPERIMENTAL | ORIC-114 dosed orally on a continuous once daily dosing regimen in 28-day cycles. |
| Combination Dose Escalation | EXPERIMENTAL | ORIC-114 dosed orally on a continuous once daily dosing regimen in 21-day cycles. |
| Name | Type | Description |
|---|---|---|
| ORIC-114 | DRUG | ORIC-114 oral daily |
| Chemotherapy drug | DRUG | 21 days for up to 4 cycles |
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |